The present application is related to coassigned U.S. patent application Ser. No. 12/888,388 entitled “DETECTION OF ANALYTES VIA NANOPARTICLE-LABELED SUBSTANCES WITH ELECTROMAGNETIC READ-WRITE HEADS”, application Ser. No. 12/888,394 entitled “READ-AFTER-WRITE DETECTION OF ANALYTES VIA NANOPARTICLE-LABELED SUBSTANCES”, U.S. patent application Ser. No. 12/888,403 entitled “A SERVO CONTROL CIRCUIT FOR DETECTING ANALYTES VIA NANOPARTICLE-LABELED SUBSTANCES WITH ELECTROMAGNETIC READ-WRITE HEADS”, and U.S. patent application Ser. No. 12/888,408 entitled “A CIRCUIT FOR DETECTING ANALYTES VIA NANOPARTICLE-LABELED SUBSTANCES WITH ELECTROMAGNETIC READ-WRITE HEADS,” all of which were filed on Sep. 22, 2010, and coassigned U.S. patent application Ser. No. 12/970,837 entitled “TRENCHED SAMPLE ASSEMBLY FOR DETECTION OF ANALYTES WITH ELECTROMAGNETIC READ-WRITE HEAD,” which was filed on Dec. 16, 2010. The contents of the related applications are hereby incorporated by reference.
The present invention relates to analytical devices and processes, and more particularly, to devices and processes that incorporate electromagnetic write-heads and magneto-resistive read-sensors to detect target antigens.
It is known that antibodies bind with antigens as part of the human disease defense system. Presently, antigens are detected by such techniques as immunofluorescence, immunoperoxidase, or enzyme-linked immunosorbent assay (ELISA), each of which then employs a microscope for visual detection of the target antigen. It is desirable to exploit the use of magnetic signaling technology to automate the detection of analytes, such as antigens, and to further apply this technology to the detection of any biological matter.
Described are embodiments of a sample assembly for detection of analytes with electromagnetic read heads.
In one embodiment, a sample assembly includes: a substrate; one or more base layers above the substrate; an outer layer above the one or more base layers; a plurality of sample trenches formed in the outer layer and/or the one or more base layers, each sample trench being characterized by an upper surface, a bottom surface, and a longitudinal axis; an electrical conductor disposed in the substrate, the electrical conductor being configured to generate an electromagnetic field in proximity to the plurality of sample trenches to enhance nanoparticle movement toward the bottom surface of the plurality of sample trenches; and at least one alignment trench formed above the substrate, each alignment trench having a longitudinal axis substantially parallel to a longitudinal axis of at least one of the sample trenches.
For a fuller understanding of the present invention, reference should be made to the following detailed description taken in conjunction with the accompanying drawings.
The invention is described in exemplary embodiments with reference to the Figures, in which like numbers represent the same or similar elements. It will be appreciated by those skilled in the art that variations may be accomplished in view of these teachings without deviating from the spirit or scope of the invention.
Exemplary embodiments of the invention relate to a sample assembly for detection of analytes with electromagnetic read heads. The substrate of the sample assembly includes an electrical conductor for generating an electromagnetic field that accelerates the bonding between target antigens in the analytes and nanoparticle-labeled antibodies. In one embodiment, the sample substrate includes a sample trench that has a first set of antibodies bonded on the bottom surface of the sample trench. The first set of antibodies are bonded to the target antigens.
Further, nanoparticles are bonded to a second set of antibodies which are then exposed to the sample trench so that the second set of antibodies are bonded with the target antigens. To speed up the bonding between nanoparticle-labeled antibodies and the target antigens, an electrical conductor embedded in or attached to the sample substrate generates an electromagnetic field that moves the nanoparticle-labeled antibodies toward the target antigens attached to the bottom of a sample trench or on the surface of a sample substrate.
A head module includes a write head for magnetizing nanoparticles and a magneto-resistive read sensor for detecting the magnetized nanoparticles, and thus, the target antigens. The sample trench constrains the biological sample, and thus the target antigens, during the preparation and subsequent analysis of the biological sample. Accordingly, the target antigens are aligned with read elements of a head module such that the target antigens are reliably and accurately detected. Further, to ensure reliable and accurate detection, an outer layer may be formed with a low friction material allowing the read head to remain in contact with the upper surface of the outer layer during the process of detection.
In one embodiment, the substrate 199 may have an outer layer 253 (
One embodiment of forming sample trenches 180 is illustrated in
Another embodiment of forming sample trenches 180 is described with respect to
Each sample trench 180 is formed having a bottom surface 255. Base layer 252 is formed within each sample trench 180 and on the bottom surface 255 of each sample trench 180. Base layer 252 may comprise nonmagnetic materials such as gold, silicon, or SiO2, or other materials having similar magnetic properties, without limitations. As shown in
As shown in
In one embodiment, as shown in
In another embodiment, magnetic encoded servo alignment marks 193 are encoded on a piece of magnetic tape which is adhered to outer layer 253. Further, the magnetic encoded servo alignment marks 193 may be encoded by the manufacturer of substrate 199 on the magnetic tape. Magnetic encoded servo alignment marks 193 may be in the form of timing based servo marks. Servo alignment marks 193 are read by read sensor 106 and used to keep the write elements 108 and read sensors 106 in alignment with sample trenches 180 along the X-axis while the head module 104 moves relative to sample trenches 180 along the Y-axis.
Still further, in one embodiment the alignment marks 193 may be non-magnetic marks. For example, the alignment marks may be lithographed, silk-screened or ink-jet printed, and read with an optical laser.
The sample trenches 180 include a biological sample having a target antigen. Sample trenches 180 act to constrain the biological sample, and thus the target antigen 210, during the preparation and subsequent analysis of the biological sample, as discussed below. For example, the sample trenches 180 prevent the biological sample from being rinsed away during a rinse step. Further, the sample trenches 180 allow the biological sample and the target antigen to be constrained to an area that is aligned with read elements 108, such that detection of target antigen 210 is reliably and accurately detected.
The preparation of the biological sample with target antigens 210 is now discussed with reference to
In step 402, a base layer 252 may be formed on the bottom surface 255 of the sample trench 180 by coating the bottom surface 255 with gold, silicon, or silicon dioxide to facilitate attaching antibodies to the sample trench 180. In step 403, antibodies 208A are bonded within sample trenches 180 to the surface of base layer 252. The antibodies 208A may be bonded within the sample trenches to the base layer 252 via bonds 206A such as amide, self-assembled-monolayers (SAMS), alkoxysilane, organic functional trialkoxysilane, thiol bonds, or the like.
In one embodiment, it is preferred that bond 206A is applied only to the surface of base layer 252. In one example, the bonding comprises coating base layer 252 with amide, self-assembled-monolayers (SAMS), alkoxysilane, or thiol, placing a solution of antibodies 208A on substrate 199, and gently rocking substrate 199 for a period of time, up to six hours. Amide refers to organic compounds that include the functional group including an acyl group, with the chemical notation C═O, linked to a nitrogen (N) atom. A SAM is an organized layer of amphiphilic molecules in which one end of the molecule, the “head group,” shows a special affinity for gold, silicon, or SiO2, such as that utilized in base layer 252. At the terminal end, the opposite end of the SAM from the “head group” is a functional group. In one embodiment, the first set of antibodies 208A are attached to this functional group in step 403. Lastly, a thiol is a compound that includes the functional group composed of a sulfur atom and a hydrogen atom (—SH). Being the sulfur analog of an alcohol group (—OH), this functional group is referred to either as a thiol group or a mercaptan group.
There are generally five known isotopes (types) of antibodies 208A and 208B for mammals. In
In one embodiment, step 403 may include rinsing substrate 199 with water or another rinsing agent to remove any antibodies 208A that are not bonded within sample trenches 180. In all rinsing steps discussed herein a surfactant may be added to the water or rinsing agent to reduce surface tension. In one example, the surfactant may include a detergent solution.
In step 404, antibodies 208A bonded within sample trench 180 are exposed to a biological sample including target antigens 210. In one example, this is accomplished by placing a blood sample or other biological sample on substrate 199. As shown in
Target antigens 210 may comprise cancer cells, viruses, or bacteria. In one embodiment, the target antigens 210 are viruses such as Human Papilloma Virus (HPV) which is known to lead to cancer. It is important to note that the antibodies 208A utilized in step 404 are specifically chosen based on the targeted antigens 210 utilized in step 406.
In one embodiment, the nanoparticles 212 may be prepared prior to bonding the nanoparticles 212 to antibodies 208B, via bonds 206B, to prevent a lumping of the nanoparticles 212 when they are magnetized. This preparation may include demagnetizing the magnetic inner cores 216, as described in the pending U.S. patent application Ser. No. 12/970,831, the content of which is herein incorporated by reference. In one embodiment, inner cores 216 are initially nonmagnetized as an artifact of their manufacturing process. In an alternate embodiment, inner cores 216 are not demagnetized.
The process in
The second antibodies 208B may be bonded to the nanoparticles 212 via amide, self-assembled-monolayers (SAMS), alkoxysilane, organic functional trialkoxysilane, or thiol bonds 206B. This bonding may be accomplished by first coating nanoparticles 212 with amide, self-assembled-monolayers (SAMS), alkoxysilane, organic functional trialkoxysilane, or thiol. It is important to note that the material used for the outer shell 214 facilitates the bonding of antibody 208B within sample trench 180. The nanoparticles 212 may be placed in a solution including the second set of antibodies 208B and gently rocking this solution for a period of time. The repetitive rocking of substrate 199 facilitates bonding of the second set of antibodies 208B with the nanoparticles 212. For example, the substrate is gently rocked for up to six hours. Further, step 502 may include a step of rinsing the sample substrate 199 with water or another rinsing agent to remove nanoparticles 212 not bonded to antibodies 208B.
In step 503, the biological sample with the target antigens 210 is exposed to the second set of antibodies 208B bonded to nanoparticles 212. This may be done by placing a solution of nanoparticle-labeled antibodies 208B on substrate 199, such as in sample trench 180. As shown in
Steps 504 and 505 may further include the repetitive rocking of substrate 199 to facilitate bonding of the target antigens 210 with antibodies 208B at antigen receptors 209B. For example, the substrate is gently rocked for up to six hours. Step 505 may include the use of an exterior auxiliary permanent magnet or an electromagnet not physically coupled to sample assembly 100 to strengthen the applied electromagnetic B field. Further, step 505 may include a step of rinsing substrate 199 with water or another rinsing agent to remove nanoparticles 212 not bonded to target antigens 210. At the conclusion of steps 504-505, the current in the conductor may be turned off so that the electromagnetic B field does not interfere with magnetizing step 506 or sensing step 507. Similarly, if auxiliary magnet 804 is used in steps 504-505, that magnet 804 may be removed at this time as well so that it does not interfere with magnetizing step 506 or sensing step 507.
In one embodiment, the substrate 199 includes an electrical conductor 601 for generating an electromagnetic field that moves the nanoparticle-labeled antibodies 208B towards the bottom of the sample trench 180 to speed up the bonding of the antibodies 208B and the target antigens 210. As illustrated in
It is preferred that the electrical conductor 701 is positioned below the plane of the bottom surface 706 so that the gradient of the electromagnetic field B (703) continues to increase as the nanoparticle-labeled antibodies 208B descend to the bottom surface 706. Empirical data indicate that the movement of the nanoparticle-labeled antibodies 208B toward the bottom surface 706 is increased by nearly two orders of magnitude times faster than their movement by gravity alone, with the nanoparticles 212 moving in water and an electric current I (702) of one ampere.
In the embodiment in which substrate 199 is a Peltier substrate, the process may include an optional step of applying a DC voltage of a first polarity to the Peltier substrate. Applying a DC voltage of a first polarity heats the surface of the substrate 199 and dries the biological sample within the sample trench 180. A DC voltage of a second and opposite polarity may be applied to Peltier substrate, to cool the surface of the substrate. In an alternate embodiment, the Peltier substrate freezes the biological sample.
Returning to
It should be understood, however, any number of sample trenches 180 may be used, and the number of electromagnetic write-head 106 and magneto-resistive read-sensor 108 pairs in head module 104 may be any number. The number may be in the range from one to the number of electromagnetic write-head and magneto-resistive read-sensor pairs the head module 104. For example, in an embodiment in which there are sixteen such electromagnetic write-head and magneto-resistive read-sensor pairs, such as in a head module of an IBM® 3480 tape drive, the number of sample trenches may be sixteen. In one embodiment, the number of sample trenches 180 is an integral multiple of the number of write-head 106 and read-sensor 108 pairs. Still further, in one embodiment, the write-head 106 and the read-sensor are not separate devices. Instead a single head may perform the functions of both the write-head 106 and read-sensor 108.
As mentioned above, the sample trenches 180 may have spacing from one sample trench to the adjacent sample trench along the X-axis to match the spacing from one read sensor 108 to the adjacent read sensor 108 along the X-axis. In one embodiment the spacing between one sample trench 180 and an adjacent sample trench 180 is 166.5 microns to match the read sensor to read sensor spacing of the IBM® TS1130 tape drive.
Write-heads 106 may be any write head known in the art. In one embodiment write-heads 106 comprise miniature electromagnets, with a coil sandwiched between two poles. Read-sensors 108 may be anisotropic magneto-resistive (AMR), giant magneto-resistive (GMR), or tunnel magneto-resistive (TMR) read-sensors, or other devices with similar functionality known in the art. GMR read-sensors, which are also known as spin-valve read-sensors, typically have an internal anti-parallel pinned layer for increased sensitivity. TMR read-sensors may utilize a tunnel barrier layer to augment the GMR internal structure and to provide increased sensitivity.
As shown in
Head module 104 is kept in linear alignment with sample trenches 180 along the X-axis by position-error-servo (PES) read-head 192, which reads magnetically encoded servo-alignment marks 193 from servo track 194 on sample assembly 100. PES read-head 192 may be, for example, an AMR, GMR, or TMR read-sensor. In the example illustrated in
In step 507 of
In one embodiment, the head module 104 comes into physical contact with the upper surface 254 of the outer layer 253 during the sweeping step of 507. Keeping the head module 104 in physical contact with the upper surface ensures that the head module 104 is kept at a known Z-axis position and assists with alignment of head module 104 with sample trenches 180. As discussed above, the outer layer 253 may comprise diamond-like-carbon, polytetrafluoroethylene, aluminum oxide, polyamides, or other low-friction materials known in the art. Accordingly, the low friction material of the outer layer assists the head module 104 to smoothly sweep the sample trenches 180 while in physical contact with the upper surface 254 of outer layer 253, such that the target antigens of the biological sample is reliably and accurately detected.
As discussed with respect to step 501 in
Write head 106 magnetizes inner cores 216 of nanoparticles 212 along the Y-axis, which is the longitudinal direction of recording in the tape drive industry. Read-sensor 108 magnetically detects nanoparticles 212 along the Y-axis. As a result in step 506, the nanoparticles 212 may be magnetized by write-head 106 and then immediately and magnetically detected by read-sensor 108 during a single sweep of the sample trenches 180. As discussed above, this process is referred to as a read-after-write operation. In one embodiment, the write-head 106 and read-sensor 108 are separated by a magnetic shield (not shown) to prevent cross-talk between write-head 106 and read-sensor 108 during step 507.
Alternatively, the steps of magnetizing nanoparticles 212 and the step of detecting the nanoparticles 212 may be performed separately. For example, write head 106 magnetizes inner cores 216 of nanoparticles 212 along the Y-axis of sample assembly 100. In one embodiment, write-head 106 is then turned off. Subsequently, read-sensor 108 magnetically detects nanoparticles 212 along the Y-axis. The read module sensor 108 may be swept across sample trenches 180 along the Y-axis in both the +Y and −Y directions. Accordingly, read-sensor 108 can repeatedly check for magnetized nanoparticles 212, thus ensuring that all target antigens 210 are detected.
In an embodiment in which the number of sample trenches 180 are greater than the number of write-head 106 and read-sensor 108 pairs in head module 104, the head module 104 may scan the sample trenches 180 in a serpentine fashion. The head module 104 performs a scan in the +Y direction, as head module 104 only provides read-after-write capability in the +Y direction as shown in
The coercivity of a magnetic inner core 216 may be chosen selectively depending upon the target antigen 210 to be detected. For example, nanoparticles 212 with magnetic inner cores 216 of different coercivity values may be respectively bonded to different types of antibodies 208A and 208B to detect various types of target antigens 210 on the sample assembly 100 simultaneously. Nanoparticles 212 may have different magnetic properties associated with each antigen-antibody combination. Read-sensor 108 detects the different magnetic properties of an inner core 216 based on the materials used for that inner core 216. As discussed above, magnetic inner cores 216 may comprise hard magnetic materials with high coercivity, such as Fe2O3, CrO2, and Barium Ferrite BaFe. For example, magnetic inner cores 216 may comprise iron oxide based nanoparticle materials, including M Fe2O4 (where M may be Co, Ni, Cu, Zn, Cr, Ti, Ba, or Mg) nanomaterials, and iron oxide coated nanoparticle materials or other structures with similar functionality. As a result, in step 507, read-sensor 108 may detect more than one type of target antigens 210 with a single sweep of the sample assembly 100.
Additionally,
Processor 161 sends control signals to power amplifier 162. Power amplifier 162 provides power to write-head 106 for magnetizing nanoparticles 212. Processor 161 also sends control signals to power amplifier 163. Power amplifier 163 powers Wheatstone bridge 164. In one embodiment, Wheatstone bridge 164 includes read-sensor 108. Thus, read-sensor receives DC current from the Wheatstone bridge 164. Read-sensor 108 detects a resistance change during step 507 discussed above. The resistance change is based on the magnetic field provided by the magnetized inner cores 216 of nanoparticles 212. Wheatstone bridge 164 balances out the zero-magnetism resistance of read-sensor 108 such that only the change in resistance of read-sensor 108 is sent to amplifier 165. The amplifier 165 receives the change in resistance and sends the change in resistance to processor 161 through filter 166. Filter 166 filters out noise. In one embodiment, filter 166 filters out 60 Hz noise which is the type of noise that is pervasive in an office or laboratory setting in which processes of the invention may be performed.
Processor 161 includes a matched filter 167 and a table 168. Processor 161 determines if a nanoparticle 212 was detected, and thus, if a target antigen 210 has been detected. The change in resistance of read-sensor 108 is directly proportional to the magnetic field provided by nanoparticle 212. The change in resistance of read-sensor 108 is directly proportional to the magnetic field provided by nanoparticle 212.
As discussed above, the coercivity of a magnetic inner core 216 may be chosen selectively depending upon the target antigen 210 to be detected. For example, nanoparticles 212 with magnetic inner cores 216 of different coercivity values may be respectively bonded to different types of antibodies 208A and 208B to detect various types of target antigens 210 on the sample assembly 100 simultaneously. The identification of the target antigens 210 in the sample trenches 180 may be facilitated by a lookup table 168 in processor 161. In one embodiment, the lookup table 168 includes a list of (a) target antigens 210, (b) the antibodies 208A and 208B bonded with the target antigens 210, and (c) the coercivity of the inner cores 216 of nanoparticles 212 bonded to antibodies 208B.
In one embodiment of the invention, a correlation calculation is performed by the write and read circuit of
C(y)=∫g(η)h(η−y)dη Equation [1]
In equation [1], η is the integration variable along the Y-axis that varies as read-sensor 108 sweeps along the Y-axis. The matched filter 167 includes an impulse response h(y) of an ideal signal profile of a detected target nanoparticle 212. Since h(y) is used repetitively, it may be calculated once and stored as matched filter 167 in processor 161.
The range of correlation C(y) is between −1 and +1, where +1 represents an ideal correlation of one hundred percent (100%), and −1 indicates no correlation. The electrical waveform g(y) of each potential detection of a nanoparticle 212 by read-sensor 108 has its correlation C(y) calculated in step 507 of
In one embodiment, the results of the sweep of step 507 may be displayed to a physician or clinician to inform the physician or clinician of the presence (or absence) of target antigens 210 in the biological sample. The results may include items such as the target antigen(s) tested for, the types of antibodies used, a simple positive-detection or negative-detection indication for each antigen, the number of nanoparticles detected for each antigen to give an indication of the prevalence of the targeted antigen, and the number of rejected detections based on the correlation calculation.
The terms “certain embodiments”, “an embodiment”, “embodiment”, “embodiments”, “the embodiment”, “the embodiments”, “one or more embodiments”, “some embodiments”, and “one embodiment” mean one or more (but not all) embodiments unless expressly specified otherwise. The terms “including”, “comprising”, “having” and variations thereof mean “including but not limited to”, unless expressly specified otherwise. The enumerated listing of items does not imply that any or all of the items are mutually exclusive, unless expressly specified otherwise. The terms “a”, “an” and “the” mean “one or more”, unless expressly specified otherwise.
Devices that are in communication with each other need not be in continuous communication with each other, unless expressly specified otherwise. In addition, devices that are in communication with each other may communicate directly or indirectly through one or more intermediaries. Additionally, a description of an embodiment with several components in communication with each other does not imply that all such components are required. On the contrary a variety of optional components are described to illustrate the wide variety of possible embodiments.
Further, although process steps, method steps, algorithms or the like may be described in a sequential order, such processes, methods and algorithms may be configured to work in alternate orders. In other words, any sequence or order of steps that may be described does not necessarily indicate a requirement that the steps be performed in that order. The steps of processes described herein may be performed in any order practical. Further, some steps may be performed simultaneously, in parallel, or concurrently.
While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that, based upon the teachings herein changes and modification may be made without departing form this invention and its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as are within the true spirit and scope of this invention. Furthermore, it is to be understood that the invention is solely defined by the appended claims.
Number | Name | Date | Kind |
---|---|---|---|
2376965 | Hellkvist | May 1945 | A |
2948624 | Watson et al. | Aug 1960 | A |
3823276 | Maslowski et al. | Jul 1974 | A |
4062047 | Scull | Dec 1977 | A |
4292920 | Smith et al. | Oct 1981 | A |
5005096 | Krounbi et al. | Apr 1991 | A |
5146004 | Morris et al. | Sep 1992 | A |
5189571 | Murphy et al. | Feb 1993 | A |
5206159 | Cohen et al. | Apr 1993 | A |
5206590 | Dieny et al. | Apr 1993 | A |
5331493 | Schwarz | Jul 1994 | A |
5376965 | Nagasaki et al. | Dec 1994 | A |
5452164 | Cole et al. | Sep 1995 | A |
5465185 | Heim et al. | Nov 1995 | A |
5615065 | Cheung | Mar 1997 | A |
5661039 | Kung et al. | Aug 1997 | A |
5689384 | Albrecht et al. | Nov 1997 | A |
5689394 | Esser et al. | Nov 1997 | A |
5736349 | Sasaki et al. | Apr 1998 | A |
5764567 | Parkin | Jun 1998 | A |
5840889 | Cavalieri et al. | Nov 1998 | A |
5863507 | James | Jan 1999 | A |
5922537 | Ewart et al. | Jul 1999 | A |
5948624 | Rothschild et al. | Sep 1999 | A |
6013531 | Wang et al. | Jan 2000 | A |
6021013 | Albrecht et al. | Feb 2000 | A |
6027946 | Weitschies et al. | Feb 2000 | A |
6282051 | Albrecht et al. | Aug 2001 | B1 |
6320719 | Albrecht et al. | Nov 2001 | B1 |
6432346 | Hall | Aug 2002 | B1 |
6462904 | Albrecht et al. | Oct 2002 | B1 |
6493172 | Morris et al. | Dec 2002 | B1 |
6548311 | Knoll | Apr 2003 | B1 |
6643084 | Andrew et al. | Nov 2003 | B1 |
6736978 | Porter et al. | May 2004 | B1 |
6770489 | Enpuku | Aug 2004 | B1 |
6962685 | Sun | Nov 2005 | B2 |
7153366 | Chen et al. | Dec 2006 | B1 |
7342738 | Anderson et al. | Mar 2008 | B1 |
7556863 | Berning et al. | Jul 2009 | B2 |
7639448 | Haustein et al. | Dec 2009 | B2 |
7639488 | Tu | Dec 2009 | B2 |
7649708 | Winarski et al. | Jan 2010 | B2 |
7649709 | Winarski et al. | Jan 2010 | B2 |
7679858 | Winarski et al. | Mar 2010 | B2 |
7960184 | Morozov et al. | Jun 2011 | B2 |
8694280 | Awezec et al. | Apr 2014 | B2 |
9034660 | Boday et al. | May 2015 | B2 |
9081004 | Boday et al. | Jul 2015 | B2 |
9304130 | Boday et al. | Apr 2016 | B2 |
9435800 | Bates et al. | Sep 2016 | B2 |
20020001960 | Wu et al. | Jan 2002 | A1 |
20020030044 | Brown | Mar 2002 | A1 |
20020119470 | Nerenberg et al. | Aug 2002 | A1 |
20020174453 | Daniell et al. | Nov 2002 | A1 |
20030077616 | Lomas | Apr 2003 | A1 |
20030077642 | Fritsch et al. | Apr 2003 | A1 |
20030186465 | Kraus et al. | Oct 2003 | A1 |
20040002125 | Gombrich et al. | Jan 2004 | A1 |
20040061968 | Fukushima et al. | Apr 2004 | A1 |
20040080855 | Tsuchiya et al. | Apr 2004 | A1 |
20040132220 | Fish | Jul 2004 | A1 |
20040166508 | Pawlak et al. | Aug 2004 | A1 |
20040219361 | Cui et al. | Nov 2004 | A1 |
20040219631 | Yokozeki et al. | Nov 2004 | A1 |
20050087000 | Coehoorn et al. | Apr 2005 | A1 |
20050100930 | Wang et al. | May 2005 | A1 |
20060020371 | Ham et al. | Jan 2006 | A1 |
20060040273 | Chaiken et al. | Feb 2006 | A1 |
20060051237 | Wang et al. | Mar 2006 | A1 |
20060128035 | Coehoorn et al. | Jun 2006 | A1 |
20060216696 | Goguen | Sep 2006 | A1 |
20070054154 | Leu | Mar 2007 | A1 |
20070115578 | Winarski et al. | May 2007 | A1 |
20070146715 | Potyrailo et al. | Jun 2007 | A1 |
20070146925 | Haustein et al. | Jun 2007 | A1 |
20080012119 | Otremba et al. | Jan 2008 | A1 |
20080036450 | Kahlman et al. | Feb 2008 | A1 |
20080206104 | Prins et al. | Aug 2008 | A1 |
20080226917 | Zhong et al. | Sep 2008 | A1 |
20090021856 | Winarski et al. | Jan 2009 | A1 |
20090027801 | Winarski et al. | Jan 2009 | A1 |
20090047520 | Lee et al. | Feb 2009 | A1 |
20090066318 | Kahlman et al. | Mar 2009 | A1 |
20090072815 | Kahlman et al. | Mar 2009 | A1 |
20090104707 | Wang et al. | Apr 2009 | A1 |
20090152657 | Suh et al. | Jun 2009 | A1 |
20090170212 | Van Der Wijk et al. | Jul 2009 | A1 |
20090212768 | Llandro et al. | Aug 2009 | A1 |
20090243594 | Kahlman | Oct 2009 | A1 |
20090268325 | Iben et al. | Oct 2009 | A1 |
20090273857 | Iben et al. | Nov 2009 | A1 |
20090314066 | Nieuwenhuis et al. | Dec 2009 | A1 |
20100017922 | Shin et al. | Jan 2010 | A1 |
20100021708 | Kong et al. | Jan 2010 | A1 |
20100093119 | Shimizu | Apr 2010 | A1 |
20100147003 | Ueda et al. | Jun 2010 | A1 |
20110053289 | Lowe et al. | Mar 2011 | A1 |
20110070440 | Linhardt et al. | Mar 2011 | A1 |
20110076670 | Boday et al. | Mar 2011 | A1 |
20110076726 | Lakey et al. | Mar 2011 | A1 |
20110076782 | Awezec et al. | Mar 2011 | A1 |
20110077869 | Boday et al. | Mar 2011 | A1 |
20110077902 | Awezec et al. | Mar 2011 | A1 |
20110262955 | Licher et al. | Oct 2011 | A1 |
20110293940 | Tokoro et al. | Dec 2011 | A1 |
20120157330 | Boday et al. | Jun 2012 | A1 |
20120164717 | Irudayaraj | Jun 2012 | A1 |
20120280675 | Berman et al. | Nov 2012 | A1 |
20120283976 | Berman et al. | Nov 2012 | A1 |
20140080118 | Bates et al. | Mar 2014 | A1 |
20160018392 | Boday et al. | Jan 2016 | A1 |
20160223533 | Boday et al. | Aug 2016 | A1 |
20160274099 | Bates et al. | Sep 2016 | A1 |
Number | Date | Country |
---|---|---|
1454851 | Nov 2003 | CN |
1783219 | Jun 2006 | CN |
1967660 | May 2007 | CN |
101509919 | Aug 2009 | CN |
101558313 | Oct 2009 | CN |
101632018 | Jan 2010 | CN |
2073016 | Jun 2009 | EP |
2005010542 | Feb 2005 | WO |
2006047840 | May 2006 | WO |
2008102218 | Aug 2008 | WO |
2009039437 | Mar 2009 | WO |
2009083856 | Jul 2009 | WO |
2009157739 | Dec 2009 | WO |
Entry |
---|
Boday et al., U.S. Appl. No. 12/970,837, filed Dec. 16, 2010. |
Restriction Requirement from U.S. Appl. No. 12/970,837, dated Jan. 29, 2013. |
Non-Final Office Action from U.S. Appl. No. 12/970,837, dated May 10, 2013. |
Final Office Action from U.S. Appl. No. 12/970,837, dated Nov. 22, 2013. |
Notice of Allowance from U.S. Appl. No. 12/970,837, dated Jan. 8, 2015. |
Bates et al., U.S. Appl. No. 13/616,855, filed Sep. 14, 2012. |
Non-Final Office Action from U.S. Appl. No. 13/616,855, dated Jun. 4, 2013. |
Non-Final Office Action from U.S. Appl. No. 13/616,855, dated Dec. 30, 2013. |
Final Office Action from U.S. Appl. No. 13/616,855, dated Jul. 24, 2014. |
Office Action from German Application No. 112011104401.1, dated May 13, 2015. |
Chinese Office Action from Application No. 201180060053.7 dated Jun. 27, 2014. |
International Search Report and Written Opinion from International Application No. PCT/EP2011/070578, dated Mar. 19, 2012. |
Awezec et al., U.S. Appl. No. 12/888,394, filed Sep. 22, 2010. |
Awezec et al., U.S. Appl. No. 12/888,403, filed Sep. 22, 2010. |
Boday et al., U.S. Appl. No. 12/888,408, filed Sep. 22, 2010. |
Boday et al., U.S. Appl. No. 12/888,388, filed Sep. 22, 2010. |
Crowther, J., “The ELISA Guidebook,” Humana Press, Totowa, New Jersey, 2001, pp. 1-425. |
Fox et al., “Tear and Serum Antibody Levels in Ocular Herpetic Infection: Diagnostic Precision of Secretory IgA,” British Journal of Ophthalmology, vol. 70, 1986, pp. 584-588. |
Liu et al., “Discrimination of specific and non-specific bindings by dielectrophoretic repulsion in on-chip magnetic bioassays,” Journal of Biosensors and Bioelectronics, No. 24, 2009, pp. 2294-2297. |
Llandro et al., “Magnetic biosensor technologies for medical applications: a review,” Med. and Biol. Eng. and Computing, Springer Berlin, Jun. 15, 2010, 22 Pages. |
Millen et al., “Giant Magenetoresistive Sensors. 2. Detection of Biorecognition Events at Self-Referencing and Magnetically Tagged Arrays”, Analytical Chemistry, vol. 80, No. 21, pp. 7940-7946, Nov. 1, 2008. |
Nordling et al., “Giant Magnetoresistance Sensors. 1. Internally Calibrated Readout of Scanned Magnetic Arrays,” Anal. Chem., vol. 80, 2008, pp. 7930-7939. |
Osterfeld et al., “Multiplex protein assays based on real-time magnetic nanotag sensing,” PNAS, vol. 105, No. 52. Dec. 30, 2008, pp. 20637-20640. |
Piedade et al., “A New Hand-Held Microsystem Architecture for Biological Analysis,” IEEE Trans. on Circuits and Systems—I: Regular Papers, vol. 53, No. 11, Nov. 2006, pp. 2384-2395. |
Schuurs et al., “Enzyme-Immunoassay,” Clini Chim Acta, vol. 81, 1977, pp. 1-40. |
Shen et al., “Detection of DNA labeled with magnetic nanoparticles using MgO-based magnetic tunnel junction sensors,” Journal of Applied Physics, vol. 103, 2008, pp. 07 A306-1-07 A306-3. |
Yammamoto et al., “Active immobilization of biomolecules on a hybrid three-dimensional nanoelectrode by dielectrophoresis for single-biomolecule study,” Nanotechnology, vol. 18,2007,495503, pp. 1-7. |
Statement of Relevance of Non-Translated Foreign Document WO2009157739. |
Boday et al., U.S. Appl. No. 14/869,734, filed Sep. 29, 2015. |
Non-Final Office Action from U.S. Appl. No. 13/616,855, dated Nov. 20, 2015. |
Notice of Allowance from U.S. Appl. No. 12/970,837, dated Jan. 7, 2016. |
Supplemental Notice of Allowance from U.S. Appl. No. 12/970,837, dated Mar. 1, 2016. |
Notice of Allowance from U.S. Appl. No. 13/616,855, dated Mar. 15, 2016. |
Boday et al., U.S. Appl. No. 15/096,175, filed Apr. 11, 2016. |
Supplemental Notice of Allowance from U.S. Appl. No. 13/616,855, dated Apr. 19, 2016. |
Bates et al., U.S. Appl. No. 15/169,340, filed May 31, 2016. |
Awezec et al., U.S. Appl. No. 61/246,329 filed Sep. 28, 2009. |
Final Office Action from U.S. Appl. No. 13/099,360, dated Feb. 25, 2014. |
Non-Final Office Action from U.S. Appl. No. 13/099,360, dated Oct. 1, 2013. |
Notice of Allowance from U.S. Appl. No. 13/099,358, dated Sep. 15, 2014. |
Notice of Allowance from U.S. Appl. No. 13/099,360, dated Jun. 4, 2014. |
Restriction Requirement from U.S. Appl. No. 13/099,358, dated Jun. 20, 2014. |
Advisory Action from U.S. Appl. No. 12/888,388, dated Jul. 25, 2013. |
Final Office Action from U.S. Appl. No. 12/888,388, dated May 9, 2013. |
Notice of Allowance from U.S. Appl. No. 12/888,388, dated Jan. 12, 2015. |
Non-Final Office Action from U.S. Appl. No. 12/888,388, dated Jan. 7, 2013. |
Restriction Requirement from U.S. Appl. No. 12/888,388, dated Aug. 28, 2012. |
Non-Final Office Action from U.S. Appl. No. 12/888,394, dated Oct. 7, 2013. |
Restriction Requirement from U.S. Appl. No. 12/888,394, dated Dec. 10, 2012. |
Final Office Action from U.S. Appl. No. 12/888,403, dated Feb. 21, 2013. |
Notice of Allowance from U.S. Appl. No. 12/888,403, dated Nov. 22, 2013. |
Non-Final Office Action from U.S. Appl. No. 12/888,403, dated Jun. 14, 2013. |
Non-Final Office Action from U.S. Appl. No. 12/888,403, dated Sep. 20, 2012. |
Advisory Action from U.S. Appl. No. 12/888,408, dated Feb. 26, 2015. |
Final Office Action from U.S. Appl. No. 12/888,408, dated Dec. 10, 2014. |
Non-Final Office Action from U.S. Appl. No. 12/888,408 dated May 23, 2014. |
Non-Final Office Action from U.S. Appl. No. 14/869,734, dated Jun. 6, 2018. |
Restriction Requirement from U.S. Appl. No. 15/096,175, dated Jul. 27, 2018. |
Non-Final Office Action from U.S. Appl. No. 15/169,340, dated Jul. 27, 2018. |
Number | Date | Country | |
---|---|---|---|
20160274102 A1 | Sep 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13616855 | Sep 2012 | US |
Child | 15169479 | US |